Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aventis Pharma: Sales jumps, margins dip - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Apr 18, 2002

    Aventis Pharma: Sales jumps, margins dip

    The results declared by Aventis pharma generate mixed reactions. While sales growth for the company has been better than expected, a fairly sharp drop in margins is discouraging. The company has recorded a sales growth of 14% from Rs 1.3 bn to Rs 1.5 bn in the first quarter of current year (FY03). However, the results for FY03 are on a merged basis with Rhone Poulenc Rorer (RPR) and hence not exactly comparable.

    (Rs m) 1QFY02 1QFY03 Change
    Net Sales 1,178 1,347 14.3%
    Other Income 40 24 -40.0%
    Expenditure 985 1,165 18.3%
    Operating Profit (EBDIT) 193 182 -5.7%
    Operating Profit Margin (%) 16.4% 13.5%  
    Interest 7 2 -71.4%
    Depreciation 38 37 -2.6%
    Profit before Tax 188 167 -11.2%
    Exceptional Items 110 (17)  
    Tax 96 43 -55.2%
    Profit after Tax/(Loss) 202 107 -47.0%
    Net profit margin (%) 17.1% 7.9%  
    No. of Shares (eoy) (m) 23 23  
    Diluted Earnings per share* 35.1 18.6  
    P/E (at current price)   23.1  
    (*- annualised)      

    Sales growth has been mainly fuelled by 32% rise in exports, mainly bulk exports to Russian and CIS countries. Contribution of exports to total sales has jumped from 18% in FY02 to 21% in 1QFY03. Encouragingly, domestic sales growth of 10% has outpaced pharma industry growth rate. The key strategic products viz, Cardace (45%), Amaryl (50%) and Allegra (26%) continued to log healthy growth rates. The drop in operating margins was mainly on the back of integration of low margin RPR business and higher provisioning for marketing expenses. Operating margins recorded a 260 basis points decline from 15% to 12%.

    The product introduction from the parent company has remained strong in case of Aventis Pharma. With the merger of its subsidiary Rhone Poulenc Rorer, Aventis Pharma product portfolio now boasts of 11 of the top 14 products of the parent company. The parent company is also expected to launch its new anti-diabetes product 'Lantus' in mid 2003. 'Lantus' has already met with good success in US and Europe.

    At the current market price of Rs 435, the stock trades at a P/e of 13x its FY03 expected earnings. The stock price of the company has run up on the back of strong performance recorded by the company for FY02. However, valuations are still at a discount when compared to its peers mainly due to lack of clarity over the recent DPCO order. While it would be futile to bet over the exact implications of the DPCO order, the negatives seem to be discounted in the current price. Any positive development on this front, could be a strong point for a re-rating of the stock. While we would consider revising our profit estimates down on the back of drop in margins, we expect margins to improve in the coming quarters on the back of changing therapeutic mix of the company and strong product flow from the parent's stable.



    Equitymaster requests your view! Post a comment on "Aventis Pharma: Sales jumps, margins dip". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 21, 2017 (Close)


    • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Financial Information With Charts